Biomarkers of Rheumatoid Arthritis–Associated Interstitial Lung Disease
Authors:
Open Access
- 9 October 2014
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 67 (1) , 28-38
Abstract
Objective: Interstitial lung disease (ILD) is a relatively common extraarticular manifestation of rheumatoid arthritis (RA) that contributes significantly to disease burden and excess mortality. The purpose of this study was to identify peripheral blood markers of RA‐associated ILD that can facilitate earlier diagnosis and provide insight regarding the pathogenesis of this potentially devastating disease complication.Methods: Patients with RA who were enrolled in a well‐characterized Chinese identification cohort or a US replication cohort were subclassified as having RA–no ILD, RA–mild ILD, or RA–advanced ILD, based on high‐resolution computed tomography scans of the chest. Multiplex enzyme‐linked immunosorbent assays (ELISAs) and Luminex xMAP technology were used to assess 36 cytokines/chemokines, matrix metalloproteinases (MMPs), and acute‐phase proteins in the identification cohort. Unadjusted and adjusted logistic regression models were used to quantify the strength of association between RA‐ILD and biomarkers of interest.Results: MMP‐7 and interferon‐γ–inducible protein 10 (IP‐10)/CXCL10 were identified by multiplex ELISA as potential biomarkers for RA‐ILD in 133 RA patients comprising the Chinese identification cohort (50 RA–no ILD, 41 RA‐ILD, 42 RA–indeterminate ILD). The findings were confirmed by standard solid‐phase sandwich ELISA in the Chinese identification cohort as well as an independent cohort of US patients with RA and different stages of ILD (22 RA–no ILD, 49 RA‐ILD, 15 RA–indeterminate ILD), with statistically significant associations in both unadjusted and adjusted logistic regression analyses.Conclusion: Levels of MMP‐7 and IP‐10/CXCL10 are elevated in the serum of RA patients with ILD, whether mild or advanced, supporting their value as pathogenically relevant biomarkers that can contribute to noninvasive detection of this extraarticular disease complication.Keywords
Funding Information
- American College of Rheumatology Research and Education Foundation (WOR Award)
- U.S. Department of Veterans Affairs (1I01BX000788)
This publication has 38 references indexed in Scilit:
- Asymptomatic Preclinical Rheumatoid Arthritis-Associated Interstitial Lung DiseaseJournal of Immunology Research, 2013
- Subclinical Interstitial Lung Disease: Why You Should CareAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Peripheral Blood Proteins Predict Mortality in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Lung Volumes and Emphysema in Smokers with Interstitial Lung AbnormalitiesNew England Journal of Medicine, 2011
- Identification of Early Interstitial Lung Disease in Smokers from the COPDGene StudyAcademic Radiology, 2010
- Characterization and peripheral blood biomarker assessment of anti–Jo‐1 antibody–positive interstitial lung diseaseArthritis & Rheumatism, 2009
- MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary FibrosisPLOS Medicine, 2008
- Roger S. Mitchell Lecture. Rheumatoid Lung DiseaseProceedings of the American Thoracic Society, 2007
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988